Get the Weekly Intelligence Brief — top committee picks every Sunday.
A · NYSE · STOCK

Agilent Technologies (A) Stock Analysis

Healthcare Updated August 23, 2026
$159.00
52W $108.35 – $160.47
58/100
$44.89B
31.8
1.23
AI Committee Verdict
Buy
58/100
Conviction: Moderate · 67% agreement · 6 analysts
+0.4%
-7.1%
0.05:1
Moderate
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.

Is A Bullish or Bearish?

Bullish. Innellis AI committee rates Agilent Technologies (A) Buy with a composite score of 58/100 , based on 6 analysts with 67% agreement. Last updated August 23, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +17.36 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -2.64 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The primary driver is news sentiment is positive (+0.33 across 9 articles, 14d). The main limiting factor is bollinger bandwidth of 17.6% signals elevated volatility. The committee is constructive but not yet at full conviction.

Bull & Bear Case

Bull Case
  • ROE of 20.8% shows genuine earnings power backing the valuation — Value
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
  • News sentiment is positive (+0.33 across 9 articles, 14d) — News
Bear Case
  • P/E of 29.4 is moderate-to-rich — Value
  • Price-to-book of 6.2x prices in significant intangible value — Value
  • RSI at 89 is in overbought territory — Technical
  • Price trading above the upper Bollinger Band -- stretched — Technical
  • Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
  • Bollinger bandwidth of 17.6% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 23, 2026
Overall Committee Score
58/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 54%
of 192 Healthcare peers
Value Analyst neutral
54 / 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 20.8% shows genuine earnings power backing the valuation
− P/E of 29.4 is moderate-to-rich
Growth Analyst bullish
62 / 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst bullish
61 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− RSI at 89 is in overbought territory
Risk Analyst bearish
35 / 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 17.6% signals elevated volatility
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst bullish
68 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.33 across 9 articles, 14d)
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3069.37)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 57.6 to 57.6.

Comparing 2026-08-22 to 2026-08-23 (1 day apart).

Technical Analysis

RSI (14)
89.3
Overbought
MACD Histogram
1.017
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Support
$147.78
Resistance
$159.59
Bollinger %B
1.01
Above Upper Band
Price vs Moving Averages
EMA 9
$151.96 Above
EMA 21
$146.61 Above
EMA 50
$139.31 Above
EMA 200
$130.78 Above

Fundamental Analysis

Valuation
46
Growth
59
Profitability
94
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio 31.8×
P/B Ratio 6.32×
PEG Ratio 1.41
Dividend Yield 0.64%
52W High $160.47
52W Low $108.35
Quality & Growth
ROE 1933.0%
ROA 1023.8%
Gross Margin 5300.1%
Operating Margin 2150.2%
Revenue Growth YoY
Debt / Equity 0.47
AI Fundamental Assessment
P/E ratio of 31.8 (rich relative to a 15-40x range); Price-to-book of 6.3x; PEG ratio of 1.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 19.3%; Return on assets of 10.2%; Net margin of 19.6%; Gross margin of 53.0%; Current ratio of 2.10 (healthy short-term liquidity); Debt-to-equity of 0.47; Free cash flow per share is positive (4.44); Most recent quarter beat estimates by 3.8%; EPS growth accelerating (-14.5% -> +9.6% QoQ); Analyst estimates falling over recent quarters
Get the Full A Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime